The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis.
ETS homologous factor
histological marker
metastasis
prostate cancer
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
24 Mar 2022
24 Mar 2022
Historique:
received:
25
02
2022
revised:
22
03
2022
accepted:
23
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
The main aim of this study was to investigate the risk of prostate cancer metastasis formation associated with the expression of ETS homologous factor (EHF) in a cohort of bioptic samples. To this end, the expression of EHF was evaluated in a cohort of 152 prostate biopsies including primary prostate cancers that developed metastatic lesions, primary prostate cancers that did not develop metastasis, and benign lesions. Data here reported EHF as a candidate immunohistochemical prognostic biomarker for prostate cancer metastasis formation regardless of the Gleason scoring system. Indeed, our data clearly show that primary lesions with EHF positive cells ≥40% had a great risk of developing metastasis within five years from the first diagnosis. Patients with these lesions had about a 40-fold increased risk of developing metastasis as compared with patients with prostate lesions characterized by a percentage of EHF positive cells ≤30%. In conclusion, the immunohistochemical evaluation of EHF could significantly improve the management of prostate cancer patients by optimizing the diagnostic and therapeutic health procedures and, more important, ameliorating the patient's quality of life.
Identifiants
pubmed: 35453848
pii: diagnostics12040800
doi: 10.3390/diagnostics12040800
pmc: PMC9025154
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Clin Lab Sci. 2021 Jul;51(4):470-486
pubmed: 34452885
Mol Carcinog. 2016 Jun;55(6):1048-59
pubmed: 26258986
Oncotarget. 2016 Nov 22;7(47):76756-76768
pubmed: 27732936
Front Oncol. 2019 May 09;9:385
pubmed: 31143708
J Biochem. 2018 Oct 1;164(4):257-264
pubmed: 29726955
BMC Med Genomics. 2022 Feb 8;15(1):24
pubmed: 35135561
Nucleic Acids Res. 2014 Dec 16;42(22):13588-98
pubmed: 25414352
J Clin Invest. 2016 Dec 1;126(12):4585-4602
pubmed: 27820701
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Microsc Res Tech. 2018 Jul;81(7):745-748
pubmed: 29633435
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Cytokine. 2022 Feb;150:155778
pubmed: 34920230
Front Oncol. 2020 Apr 07;10:499
pubmed: 32318352
Contrast Media Mol Imaging. 2018 Dec 9;2018:9840962
pubmed: 30627063
Nutr Metab Cardiovasc Dis. 2019 Dec;29(12):1330-1336
pubmed: 31653516
Cancer Res. 2016 Jun 15;76(12):3629-43
pubmed: 27197175
Gut. 2022 Feb;71(2):357-371
pubmed: 33674341
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Med. 2021 Oct 21;10(21):
pubmed: 34768368
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807717
Cell Death Discov. 2021 Dec 4;7(1):373
pubmed: 34864817
Cell Death Dis. 2021 Jan 5;12(1):46
pubmed: 33414441
Molecules. 2018 Aug 30;23(9):
pubmed: 30200227
Urol Oncol. 2019 May;37(5):297.e19-297.e31
pubmed: 30827759
BMJ Open. 2021 Feb 11;11(2):e040531
pubmed: 33574142
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Histopathology. 2019 Jan;74(1):146-160
pubmed: 30565302
Oncogene. 2013 May 2;32(18):2315-24, 2324.e1-4
pubmed: 22733135
Cancers (Basel). 2020 Oct 14;12(10):
pubmed: 33066424
Oncogenesis. 2021 Mar 12;10(3):26
pubmed: 33712555
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15312-7
pubmed: 22949650
Oncol Rep. 2021 Jun;45(6):
pubmed: 33907840
Arch Pharm Res. 2019 Jan;42(1):14-24
pubmed: 30649699
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
World J Gastroenterol. 2020 Dec 21;26(47):7497-7512
pubmed: 33384550
Development. 2021 Jun 15;148(12):
pubmed: 34180969
Semin Cell Dev Biol. 2018 Jun;78:22-36
pubmed: 29258963